Skip to main content
Cyber Week Sale - Get 40% off Vantage
Published loading...Updated

Celltrion receives Health Canada approval for Eydenzelt®, a biosimilar referencing Eylea® (aflibercept 2mg)

Summary by Financial Post
TORONTO, Ontario -- Celltrion, Inc. today announced that Health Canada has approved Eydenzelt®, a biosimilar referencing Eylea® (aflibercept 2mg), in both vial and pre-filled syringe format, for treatment of all indications approved for Eylea.1

Bias Distribution

  • 100% of the sources lean Right
100% Right

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

Financial Post broke the news in Canada on Thursday, November 27, 2025.
Too Big Arrow Icon
Sources are mostly out of (0)

Similar News Topics

News
Feed Dots Icon
For You
Search Icon
Search
Blindspot LogoBlindspotLocal